Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.
June 22, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $200 price target.
The news is directly related to Alnylam Pharmaceuticals as Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating and maintained a $200 price target. This indicates that the analyst's view on the stock remains unchanged, which is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100